NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FOR CAR T-CELL THERAPY ACROSS EUROPE

A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients.  The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patients.

Read the full report here